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Abstract
Background: If the randomisation process within a trial is subverted, this can lead to selection bias that may
invalidate the trial’s result. To avoid this problem, it is recommended that some form of concealment should be put
into place. Despite ongoing anecdotal concerns about their susceptibility to subversion, a surprising number of
trials (over 10%) still use sealed opaque envelopes as the randomisation method of choice. This is likely due in part
to the paucity of empirical data quantifying the potential effects of subversion. In this study we report a historical
before and after study that compares the use of the sealed envelope method with a more secure centralised
telephone allocation approach in order to provide such empirical evidence of the effects of subversion.
Methods: This was an opportunistic before and after study set within a multi-centre surgical trial, which involved
654 patients from 28 clinicians from 23 centres in the UK and Ireland. Two methods of randomly allocating subjects
to alternative treatments were adopted: (a) a sealed envelope system administered locally, and (b) a centralised
telephone system administered by the trial co-ordination centre. Key prognostic variables were compared between
randomisation methods: (a) age at trial entry, a key prognostic factor in the study, and (b) the order in which
‘randomisation envelopes’ were matched to subjects.
Results: The median age of patients allocated to the experimental group with the sealed envelope system, was
significantly lower both overall (59 vs 63 years, p < 0.01) and in particular for three clinicians (57 vs 72, p < 0.01; 33
vs 69, p < 0.001; 47 vs 72, p = 0.03). No differences in median age were found between the allocation groups for the
centralised system.
Conclusions: Due to inadequate allocation concealment with the sealed envelope system, the randomisation
process was corrupted for patients recruited from three clinicians. Centralised randomisation ensures that treatment
allocation is not only secure but seen to be secure. Where this proves to be impossible, allocation should at least
be performed by an independent third party. Unless it is an absolute requirement, the use of sealed envelopes
should be discontinued forthwith.
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Background
It is widely accepted that randomised controlled trials are
the method of choice for the evaluation of new clinical
treatments. They differ from other prospective designs
principally in the way in which the groups for comparison
are generated. True random allocation leads to groups at
trial entry that differ only by chance in potentially con-
founding prognostic factors, both known and unrecog-
nised [1, 2].
Failure to secure random allocation can lead to selection
bias that invalidates a trial’s results [3–6]. Knowledge of
the next allocation may bias the decision to recruit a per-
son or lead to participants with a better prognosis being
assigned to one group rather than another [7]. Eliminating
selection bias at trial entry requires two things: first, un-
predictable sequencing of allocations, and second, secure
allocation concealment, such that ‘irretrievable’ trial entry
occurs before the assigned treatment is known [7].
If the allocation is deciphered this can lead to the possi-
bility of subverting the randomisation, which introduces
selection bias. Quantifying the frequency of subversion is
difficult as it is a form of academic and clinical miscon-
duct. Nevertheless, Berger [8] has collected over 30 exam-
ples where there was concern that the allocation schedule
had been subverted and a survey of clinicians who have
had experience of recruiting participants into clinical trials
found that 16% of them kept a log of previous allocations
in order to help them predict future ones [9]. To avoid
the problem of subverting the allocations it is recom-
mended that some form of concealment should be
put into place to reduce the possibility of allocation
subversion.
The use of sealed opaque envelopes is still often used in
randomised trials, with a recent review finding that 11% of
trials published in 2016 in four major medical journals
used sealed envelopes [10]. This is despite Schulz [7]
reporting, more than 20 years ago, instances where this
approach can be manipulated by either opening envelopes
in advance or through transillumination. A methodo-
logical study [11] that compared the significance levels of
trials that mainly used sealed envelopes with those who
used more secure, third-party, randomisation systems
found that trials using less secure procedures had signifi-
cantly smaller p values than those using a more secure
allocation method. However, it was not possible in that
review to identify individual instances of misallocation
and the reporting of actual cases of misallocation is rare.
In this present study we report a before and after study
that compared the use of the sealed-envelope method with
a more secure centralised telephone-allocation approach.
Although this study took place in the mid-1990s we
believe it still has relevance today, given the continuing
prevalence of poorly concealed allocation in current
clinical trials [10].
Methods
The trial was a multi-centre randomised controlled trial in
surgery in which age was judged to be a key prognostic
variable. Age distribution was first described in an initial
cohort of 327 participants randomised using a sealed en-
velope system [12], and then compared with a similar-
sized cohort recruited after the introduction of a central
telephone randomisation system.
The sealed envelope system
The generation of the random sequence of envelope allo-
cations was performed using a matched block method
stratified by clinician. Allocation was assigned to each
block using simple randomisation; this block sequence
was then repeated swapping the order of the two treat-
ments, giving an equal number of patients in the two
treatment groups over the matched block. To ensure that
the sequence could not be anticipated the block size was
selected randomly to be 5, 10 or 15. The random sequence
for these blocks was generated using a random number
generator within the statistical analysis package SPSS, the
seed calculated by multiplying the seconds and minutes
portion of the computer’s internal clock. This generated a
pseudo-random distribution in the range 0 to 1. Values
<0.5 were allocated the control treatment, and those ≥0.5
to the experimental treatment.
These allocations were printed onto cards which were
then sealed in sequentially numbered envelopes. This
process was performed for each clinician on joining the
collaborative trial group. At randomisation, the envelope
number and patient identifying details were recorded on
a form which was then returned to the trial administra-
tion centre to confirm recruitment.
The centralised telephone randomisation system
The centralised system used a toll-free, dedicated
telephone line. To recruit a patient the clinician now
telephoned the trial administration centre giving details of
the prognostic factors. Details were entered directly into a
customised database package to generate the allocation. In
addition to stratification by clinician, the allocation was
minimised on five prognostic factors (age, sex, and three
clinical factors - site of hernia, type of hernia and presence
of recurrent hernia). These include age, which was split
into three groups; the other factors were dichotomised.
Statistical methods
For each randomisation system, the age distribution in the
trial groups was compared first for all patients, and then
for those recruited by the five clinicians who had recruited
more than 25 people in the first time period; all other
clinicians’ patients were combined to give a sixth group.
Median ages were compared using the Mann-Whitney U
test. Median differences in age between the groups (with
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95% confidence intervals) were then generated. Apparent
imbalances in the age distributions were further investi-
gated by plotting the recruitment sequence against the
envelope number, for those cases where this information
was available.
Results
Table 1 summarises the age distributions first when the
sealed envelope method was used and then when central
telephone randomisation was employed. During the first
time period the difference in the age distributions in the ex-
perimental and control groups is unlikely to reflect chance
both overall (median age 59 vs 63 years, p < 0.01) and
amongst those recruited by clinicians 3 (median age 57 vs
72 years, p < 0.01), 4 (median age 33 vs 69 years, p < 0.001),
and 5 (median age 47 vs 72 years, p = 0.03). In contrast,
differences in the period of central telephone randomisation
were compatible with chance, random variation. Figure 1
shows the median differences in age with 95% confidence
intervals, negative values indicating younger patients in the
experimental group.
Plots of the recruitment sequence against the envelope
number (Fig. 2) showed instances of skipping envelopes
completely (for example, envelopes 3, 11 and 16 were not
used at all), and evidence of envelopes being used out of
sequence (for example patients numbered 15 to 20 were al-
located using envelope numbers 14, 18, 20, 24, 22 and 23).
Discussion
This study provides one of the very few empirical exam-
ples of subversion of randomisation and the consequences
of such subversion for trial characteristics. In this study
we detected the subversion problem by testing for age
equivalence between the randomised groups. Although
baseline testing is generally not promoted (e.g. Altman
and Dore 1990 [4]) because in a properly randomised trial
any differences in baseline are most likely due to chance,
Berger [8] argues strongly that baseline testing still has a
role in order to detect possible allocation subversion. He
argues that because subversion is likely to be hidden from
the investigators baseline testing is legitimate to reassure
the investigators and readers that subversion is unlikely.
The level of subversion is, however, required to be
relatively substantial as in our example for it to effectively
identify a subversion problem. A complementary ap-
proach, if trials use block randomisation, has been sug-
gested to detect suspicious imbalances [13].
Although there is indirect and anecdotal evidence of
important bias introduced by faulty randomisation proce-
dures, investigators are understandably reluctant to de-
scribe such problems. The new surgical procedure that we
were helping to evaluate was likely to need a longer period
of general anaesthesia and so likely to be considered less
suitable for older, frailer patients. We were therefore
concerned at the apparent imbalance in age amongst the
cohort recruited during the start-up phase of this trial;
further investigations indicated that the system had been
corrupted amongst patients recruited by three clinicians
(their results were not used in the final trial analysis). The
problem was restricted to the period when a sealed
envelope method was used and was not seen after central
telephone randomisation had been instituted.
The problem was one of inadequate concealment rather
than with the generation of the sequence. There are a
number of ways in which the allocation can be prematurely
revealed before formal trial entry when sealed envelopes
are used. More than one envelope can be opened until a
desired allocation is found, the order in which patients are
recruited may be manipulated such that a particular patient
is allocated a chosen treatment, or the allocation may be
discerned without opening the envelope (such as by trans-
illumination) with the (biased) decision about trial entry
dependent on the allocation. The plots of recruitment
sequence against envelope number were used to explore
these possibilities; these should show a straight line if the
process is carried out correctly, although even this does not
rule out biased entry. We did find examples of skipping
envelopes and order changes amongst the participants
recruited by the three clinicians. Order changes are unlikely
to be an important factor; however, because in only two of
Table 1 Age distribution in trial groups: (a) using the sealed envelope method and (b) using central telephone randomization
(a) Sealed envelope method (b) Central telephone randomisation
Experimental Control Experimental Control
Clinician(s) n median (IQR) n median (IQR) p n median (IQR) n median (IQR) p
All 169 59 (40, 69) 158 63 (33, 63) <0.01 162 59 (48, 69) 165 57 (44, 67) 0.37
1 64 62 (44, 70) 66 61 (44, 72) 0.84 38 57 (42, 66) 37 57 (50, 67) 0.62
2 19 43 (35, 65) 17 52 (43, 65) 0.60 13 60 (48, 71) 12 51 (45, 59) 0.24
3 24 57 (41, 67) 19 72 (53, 76) <0.01 2 61 (-) 2 70 (-) (-)
4 13 33 (25, 41) 13 69 (51, 74) <0.001 14 63 (50, 70) 14 65 (41, 76) 0.99
5 14 47 (37, 65) 14 72 (53, 77) 0.03 12 57 (49, 71) 12 62 (34, 69) 0.91
Others 35 64 (45, 70) 29 59 (47, 71) 0.99 83 59 (48, 69) 88 56 (42, 67) 0.27
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Fig. 1 Comparison of the envelope system with the telephone system for median differences in age between the experimental and control groups
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the five times it occurred was the skipped allocation differ-
ent from the card used.
Sequentially numbered sealed envelopes remain a widely
used method for allocation in intended randomised trials,
and occasionally are the only practical method of under-
taking randomisation. For example, in a sample of ‘open’
trials published in major medical journals in 2016, about
11% were using sealed envelopes to conceal allocation [10]
Clark et al. Our experience, however, which supports the
previous anecdotal evidence reported by Berger [8] and
Brown et al. [9] illustrates why the use of envelopes is
more susceptible to corruption - often through well-
intentioned, human ingenuity rather than other ap-
proaches - and why it is a less than ideal method of con-
cealment. It also underlines the recommendation in the
Consolidated Standards of Reporting Trials (CONSORT)
statement on the reporting of randomised controlled trials
that a full description be given of the actual methods used
to generate and conceal trial allocations [14].
The mistake not to generate the allocation sequence from
the executor of the treatment assigned is clearly illustrated. If
a sealed envelope or other locally based method of random
allocation has to be used a clear message from our study is
that this should be the responsibility of an independent third
party who has no direct involvement in the trial or in patient
care. A centralised system such as the one in place for the
main recruitment period of this trial is preferable.
In this trial the method of allocation was changed from
blocked randomisation to minimisation, and allocation
was minimised by centre. Using any form of restriction to
the randomisation can, however, increase the risk of pre-
dictability and possible subversion through scheduling
[13]. Indeed, a case study has been reported where subver-
sion occurred despite using a central telephone random-
isation service [15]. This was probably caused due to use
of a predictable sequence of blocks in the randomisation.
Conclusions
In summary, this study provides further empirical evidence
that using sealed opaque sequentially numbered envelopes
is an inadequate method of concealing treatment allocation
and we recommend that, unless it is an absolute require-
ment, their use should be discontinued forthwith. Trialists
should use other means to prevent allocation subversion.
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